Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 328

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 328
---
,
refers to CERo Therapeutics Holdings, Inc. (“Successor” or the “Company”). As a result of the Merger, the results
of operations, financial position and cash flows of the Predecessor and the Company are not directly comparable. CERo Therapeutics, Inc.
was deemed to be the predecessor entity. Accordingly, the historical financial statements of CERo Therapeutics, Inc. became the historical
financial statements of the combined Company, upon the consummation of the Merger. As a result, the financial statements included in
this report reflect (i) the historical operating results of CERo Therapeutics, Inc. prior to the Merger and (ii) the combined results
of the Company, CERo Therapeutics Holdings, Inc., following the Closing. The accompanying unaudited condensed consolidated financial
statements include a Predecessor period, which includes the period through February 13, 2024 concurrent with the Merger, and a Successor
period from February 14, 2024 through September 30, 2024. A black line between the Successor and Predecessor periods has been placed
in the condensed consolidated financial statements and in the tables to the notes to the condensed consolidated financial statements
to highlight the lack of comparability between these two periods.

<div align='center'>F-10</div>

Use of estimates– The preparation
of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of
expenses incurred during the reporting period. Items subject to such estimates and assumptions include the estimates of the fair values
of acquired in-process research and development, convertible preferred stock, common stock, earnout share liabilities, stock-based compensation
expense, the present value of right-to-use assets and lease liabilities, and the valuation allowance associated with deferred tax assets.
Actual results could differ from those estimates.

Cash, restricted cash, and cash equivalents– The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or
less to be cash equivalents. As of September 30, 2024 for the Company and December 31, 2023 for Predecessor, cash and cash equivalents
consist of cash deposited with banks, including a money market sweep account. Restricted cash for Predecessor and the Company consists
of $74,756 and $74,